Search results
Innovent Presents at the 2024 ASCO Annual Meeting on Clinical Data of anti-CLDN18.2 ADC (IBI343) in...
Char-Koosta News· 5 days agoInnovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that...
Innovent Delivers Oral Presentation of Clinical Data of A Randomized Controlled Phase 1b Study...
KOIN News 6 Portland· 4 days agoInnovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that...
Innovent Presents Phase 1 Clinical Data of First-in-class PD-1/IL-2α Bispecific Antibody Fusion...
Char-Koosta News· 5 days agoInnovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that...
Innovent Delivers Oral Presentations at the 2024 ASCO Annual Meeting on Clinical Data of...
KOIN News 6 Portland· 4 days agoInnovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that...
Cell therapy reckoning: How to get cell therapies flying off-the-shelf
FierceBiotech· 7 days agoThis story is the final part of a four-part series about cell therapy created by the Fierce Biotech...
Small Business - The Roanoke-Chowan News-Herald | The Roanoke-Chowan News-Herald
Roanoke-Chowan News-Herald· 5 days agoInnovent Presents at the 2024 ASCO Annual Meeting on Clinical Data of anti-CLDN18.2 ADC (IBI343) in Patients with Advanced Pancreatic Cancer or Biliary Tract Cancer PR Newswire SAN FRANCISCO, U.S. and SUZHOU, China, June 1, 2024 SAN FRANCISCO, U
Small Business - The Roanoke-Chowan News-Herald | The Roanoke-Chowan News-Herald
Roanoke-Chowan News-Herald· 5 days agoInnovent Announces Taletrectinib(ROS1 Inhibitor)Updated Data from Pivotal Phase 2 TRUST-I Study of are Published in the JCO and Orally Presentedat 2024 ASCO Annual Meeting PR Newswire SAN FRANCISCO and SUZHOU, China, June 2, 2024 SAN FRANCISCO and